Altre lingue VYNE Therapeutics Inc.

Azioni

VYNE

US92941V3087

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/06/2024			Variaz. 5gg	Var. 1 gen.
1,73 ^USD	0,00%		-21,72%	-25,75%

24/06	Arvinas, Inc. nomina Andrew Saik come Tesoriere	CI
13/06	Vyne Therapeutics annuncia il dosaggio dei primi partecipanti allo studio di Fase 1A del nuovo inibitore Bet Bd2-selettivo Vyn202	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Arvinas, Inc. Appoints Andrew Saik as Chief Financial Officer	24/06
Arvinas, Inc. Appoints Andrew Saik as Treasurer	24/06
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202	13/06
Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202	13/06
Top Premarket Gainers	07/06
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	05/06
VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201	05/06
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q1 Revenue $98,000	09/05
VYNE Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
VYNE Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
VYNE Therapeutics Says US FDA Clears its Investigational New Drug Application for Potential Autoimmune Treatment	06/05
VYNE Therapeutics Announces FDA Clearance of IND Application for VYN202, a Novel BD2-Selective BET Inhibitor	06/05
Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor	06/05
VYNE Therapeutics Announces Oral Presentations for VYN201 at the 2024 Society for Investigative Dermatology (SID) Annual Meeting	01/05
VYNE Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	19/03
VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
VYNE Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Earnings Flash (VYNE) VYNE THERAPEUTICS Posts Q4 Revenue $76,000	29/02
VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update	29/02
VYNE Therapeutics to Present Results of the Phase 1b Trial for VYN201 at the 2024 Global Vitiligo Foundation Annual Scientific Symposium	27/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue VYNE Therapeutics Inc.

Azioni

VYNE

US92941V3087

Altre lingue

Filtri